Clincosm LogoSign in Get a demo

Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05637905
Collaborator
(none)
44
Enrollment
29
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

  1. Evaluate serum levels of (MCP-1) in PsA with or without cardiovascular affaction .

  2. Detect subclinical cardiovascular affaction in patients with PsA for early diagnosis and management .

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Psoriatic arthritis (PSA) is an autoimmune disease arising from the interply between proinflamatory cytokines

    [1]and external stimuli in genetically predisposed individuals.[2]

    • The disease is chronic and affects the peripheral joints and may include axial skeleton with or without extrarticular manifestations.[3]

    • Abnormal activation of the innate and adaptive immune systems contributes to chronic disease processes in both psoriasis and PSA .[4] The skin and the joints exhibit a prominent lymphocytic infiltrate consisting of activated CD4+ and CD8+ T cells as well as an increase in neutrophil infiltration[5].

    Patients with PsA have a higher risk of developing a cardiovascular(CV) events than the general population. This could be attributed to the higher prevalence of traditional cardiovascular risk factors and to the disease characteristics such as systemic inflammation. [6] These patients may show asymptomatic cardiomyopathy even in the absence of traditional risk factors [7].Cardiac dysfunction is associated with a poor prognosis, increased mortality, and affact socioecenomic function of patients therefore, the diagnosis of the cardiac dysfunction in the asymptomatic phase of the disease [8] is important for the timely introduction of therapy [9].Monocyte chemotactic protien1(MCP-1) is a member of chemotactic chemokines(CC) which are secreted by immune effector cells and dysfunctional endothelium [10].

    • The pivotal function of MCP-1 is to attract monocyte in the arterial wall through increased expression of adhesion molecules on their surface that interacts with endothelium[11].

    • MCP-1 induce maturation of monocyte in the arterial wall ,which then become specialized macrophage in early atheroma and produce tissue factors supporting coagulation and proinflammatory cytokines such as IL-1 and IL-6. It affects the functions of the surrounding immune effector cells in locally thickened intima.[12]

    • During active disease in psoriatic skin lesions and synovial tissue, activated monocytes represent the major source of proinflammatory mediators, including the chemokine MCP-1 [13]. MCP-1 is thought to be involved in the pathogenesis of oedema and bone erosion in patients with PsA [14].

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    44 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Other
    Official Title:
    The Predictive Value of Monocyte Chemoattractant Protein -1 in the Development of Cardiovacular Events in Psoriatic Arthritis Patients
    Anticipated Study Start Date :
    Jan 1, 2023
    Anticipated Primary Completion Date :
    Mar 1, 2023
    Anticipated Study Completion Date :
    Jun 1, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    psoriatic arthritis patients group
    health control group

    Outcome Measures

    Primary Outcome Measures

    1. MCP-1 [two month]

      :Evaluate serum levels of monocyte chemoattractant protein-1(MCP-1) in relation to echocardiographic changes in patient with psoriatic arthritis.

    Secondary Outcome Measures

    1. Echocardiography [two month]

      b.Detect subclinical cardiovascular affaction in patient with psoriatic arthritis.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • PsA patients (age ≥ 18years) who fulfilled the CASPAR classification criteria[15]for psoriatic arthritis
    Exclusion Criteria:
    • PsA patients with

    1. infection.

    2. bone marrow disorders.

    3. other autoimmune diseases.

    4. diabetes.

    5. hypertention .

    6. hyperlipidemia.

    7. liver diseases.

    8. renal diseases.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    • Study Director: Eman Abass, doctor, Assiut University
    • Study Director: Mohamed Raouf, doctor, Assiut University
    • Study Director: Esraa Ahmed, doctor, Assiut University

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Amira Anas Mostafa Mohamed, doctor, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05637905
    Other Study ID Numbers:
    • MCP-1
    First Posted:
    Dec 6, 2022
    Last Update Posted:
    Dec 6, 2022
    Last Verified:
    Nov 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Arthritis
    Arthritis, Psoriatic

    Study Results

    No Results Posted as of Dec 6, 2022